Heat Shock Protein–Inducing Compounds as Therapeutics to Restore Proteostasis in Atrial Fibrillation
| Autor: | Bianca J. J. M. Brundel, Jean-Paul G. Seerden, Femke Hoogstra-Berends, Roelien A. M. Meijering, Lizette Loen, Robert H. Henning, Harm H. Kampinga, Irma Kuipers, Deli Zhang, André Heeres |
|---|---|
| Přispěvatelé: | Biobased Ingredients and Materials |
| Rok vydání: | 2012 |
| Předmět: |
Drug
Pathology medicine.medical_specialty STRESS cardiac media_common.quotation_subject hartaandoeningen Disease Bioinformatics Heat shock protein Humans Life Science Medicine HSP70 Heat-Shock Proteins atrial fibrillation proteostasis deficiencies Sinus rhythm MOLECULAR TARGETS myocytes cardiac Paroxysmal AF media_common business.industry INDUCTION heat-shock proteins Atrial fibrillation myocytes medicine.disease Proteostasis DISEASES HSPB Disease Progression CONTRACTILE DYSFUNCTION MEMBERS Cardiology and Cardiovascular Medicine business Atrial substrate INTERVENTION |
| Zdroj: | Trends in Cardiovascular Medicine, 22(3), 62-68 Trends in Cardiovascular Medicine, 22(3), 62-68. Elsevier Trends in Cardiovascular Medicine 22 (2012) 3 Hoogstra-Berends, F, Meijering, R A M, Zhang, D, Heeres, A, Loen, L, Seerden, J-P, Kuipers, I, Kampinga, H H, Henning, R H & Brundel, B J J M 2012, ' Heat Shock Protein-Inducing Compounds as Therapeutics to Restore Proteostasis in Atrial Fibrillation ', Trends in cardiovascular medicine, vol. 22, no. 3, pp. 62-68 . |
| ISSN: | 1050-1738 |
| DOI: | 10.1016/j.tcm.2012.06.013 |
| Popis: | Atrial fibrillation (AF) is the most common clinical tachyarrhythmia associated with significant morbidity and mortality and is expected to affect approximately 30 million North Americans and Europeans by 2050. AF is a persistent disease, caused by progressive, often age-related, derailment of proteostasis resulting in structural remodeling of the atrial cardiornyocytes. It has been widely acknowledged that the progressive nature of the disease hampers the effective functional conversion to sinus rhythm in patients and explains the limited effect of current drug therapies. Therefore, research is directed at preventing new-onset AF by limiting the development of substrates underlying AF promotion. Upstream therapy refers to the use of drugs that modify the atrial substrate- or target-specific mechanisms of AF, with the ultimate aim to prevent the occurrence (primary prevention) and recurrence of the arrhythmia following (spontaneous) conversion and to prevent the progression of AF (secondary prevention). Recently, we observed that heat shock protein (HSP) inducing drugs, such as geranylgeranylacetone, prevent derailment of proteostasis and remodeling of cardiornyocytes and thereby attenuate the AF substrate in cellular, Drosophila melanogaster, and animal experimental models. Also, correlative data from human studies were consistent with a protective role of HSPs in preventing the progression from paroxysmal AF to permanent AF and in the recurrence of AF. In this review, we discuss novel HSP-inducing compounds as emerging therapeutics for the primary and secondary prevention of AF. (Trends Cardiovasc Med 2012;22:62-68) (c) 2012 Elsevier Inc. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect